GGrantIndex
← Leaderboards

M Flint Beal

Massachusetts General Hospital

Google Scholar ↗PubMed ↗ORCID ↗
$24,698,686
Attributed
$24,725,353
Total exposure
14
Grants
9
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $7M · FY2005–20
$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20

Funding mix

By agency

NIH$24,725,353 · 14

By mechanism

U01$11,136,375 · 2
R01$7,180,808 · 4
P01$3,925,638 · 4
RC2$1,453,349 · 1
P50$610,778 · 1
R21$378,405 · 1

Top collaborators

Most similar at Massachusetts General Hospital

Same institution · by research overlap

Others in their field

Top investigators on “Oxidative Stress”

Research focus

Oxidative StressLaboratory MouseMitochondriaGenetically Modified AnimalsBrainBiomarkerNeurodegenerative DisordersMouse ModelPathogenesisUbiquinoneImpairmentHuntington'S DiseaseNeural DegenerationMitochondrial DysfunctionAntioxidantsMitochondrial Disease /DisorderOxidative DamageMitochondrial DnaHuman SubjectLeadNerve DegenerationGene ExpressionClinical TrialsDeoxyguanosine

Grant awards (55)

Modulating Energy Metabolism as a Therapeutic Approach for Alzheimer's Disease$505,100
P01 · FY2020 · AG · contact PI
Modulating Energy Metabolism as a Therapeutic Approach for Alzheimer's Disease$505,100
P01 · FY2019 · AG · contact PI
NAD, PGC-1alpha and SIRT3 as Therapeutics Targets for Huntington's Disease$370,781
R01 · FY2019 · NS · contact PI
Modulating Energy Metabolism as a Therapeutic Approach for Alzheimer's Disease$505,100
P01 · FY2018 · AG · contact PI
NAD, PGC-1alpha and SIRT3 as Therapeutics Targets for Huntington's Disease$370,781
R01 · FY2018 · NS · contact PI
Modulating Energy Metabolism as a Therapeutic Approach for Alzheimer's Disease$505,098
P01 · FY2017 · AG · contact PI
NAD, PGC-1alpha and SIRT3 as Therapeutics Targets for Huntington's Disease$370,781
R01 · FY2017 · NS · contact PI
Modulating Energy Metabolism as a Therapeutic Approach for Alzheimer's Disease$506,324
P01 · FY2016 · AG · contact PI
NAD, PGC-1alpha and SIRT3 as Therapeutics Targets for Huntington's Disease$370,781
R01 · FY2016 · NS · contact PI
NAD, PGC-1alpha and SIRT3 as Therapeutics Targets for Huntington's Disease$370,781
R01 · FY2015 · NS · contact PI
Biomarkers of Oxidative Stress in Parkinson's Disease$718,001
RC2 · FY2010 · AT · contact PI
Interactions for Pesticides, mitochondria and genetics in Parkinson's disease.$422,500
R01 · FY2010 · ES · contact PI
Effects of Coenzyme Q10 in Parkinson Disease-Phase 3$9,535
U01 · FY2010 · NS · contact PI
Effects of Coenzyme Q10 in Parkinson Disease-Phase 3$5,777,812
U01 · FY2009 · NS · contact PI
Biomarkers of Oxidative Stress in Parkinson's Disease$735,348
RC2 · FY2009 · AT · contact PI
Interactions for Pesticides, mitochondria and genetics in Parkinson's disease.$481,400
R01 · FY2009 · ES · contact PI
Development of New Therapies for Huntington's Disease$358,502
U01 · FY2008 · NS · contact PI
Effects of Coenzyme Q10 in Parkinson Disease-Phase 3$1,300,000
U01 · FY2007 · NS · contact PI
Development of New Therapies for Huntington's Disease$358,502
U01 · FY2007 · NS · contact PI
Bioenergetics in Animal Models of Huntington's Disease$350,400
R01 · FY2007 · NS · contact PI
Mitochondria in Amyotrophic Lateral Sclerosis$226,649
P01 · FY2007 · NS · contact PI
Antioxidant Approaches to Alzheimer's Disease Therapy$169,245
R21 · FY2007 · AG · contact PI
Mitochondria and Oxidative Stress in Neurodegenerative Disorders$40,000
R13 · FY2007 · AG
Development of New Therapies for Huntington's Disease$369,209
U01 · FY2006 · NS · contact PI
Bioenergetics in Animal Models of Huntington's Disease$360,866
R01 · FY2006 · NS · contact PI
Mitochondria in Amyotrophic Lateral Sclerosis$236,493
P01 · FY2006 · NS · contact PI
Antioxidant Approaches to Alzheimer's Disease Therapy$209,160
R21 · FY2006 · AG · contact PI
Effects of Coenzyme Q10 in Parkinson Disease-Phase 3$2,206,627
U01 · FY2005 · NS
Development of New Therapies for Huntington's Disease$378,094
U01 · FY2005 · NS
Bioenergetics in Animal Models of Huntington's Disease$369,550
R01 · FY2005 · NS
MITOCHONDRIA AND NEURODEGENERATION IN TRANSGENIC MICE$292,743
P01 · FY2005 · AG
Mitochondria in Amyotrophic Lateral Sclerosis$233,958
P01 · FY2005 · NS
Development of New Therapies for Huntington's Disease$378,094
U01 · FY2004 · NS
Bioenergetics in Animal Models of Huntington's Disease$369,550
R01 · FY2004 · NS
Mitochondrial Dysfunction in Alzheimer's Disease$325,440
R01 · FY2004 · AG
Mitochondria in Amyotrophic Lateral Sclerosis$227,867
P01 · FY2004 · NS
Bioenergetics in Animal Models of Huntington's Disease$386,056
R01 · FY2003 · NS
Mitochondrial Dysfunction in Alzheimer's Disease$325,440
R01 · FY2003 · AG
Bioenergetics in Animal Models of Huntington's Disease$84,000
R01 · FY2003 · NS
BIOENERGETICS IN ANIMAL MODELS OF HUNTINGTONS$393,701
R01 · FY2002 · NS
Mitochondrial Dysfunction in Alzheimer's Disease$325,440
R01 · FY2002 · AG
OXIDATIVE DAMAGE AND MITOCHONDRIAL DYSFUNCTION$73,467
P50 · FY2002 · NS
Mitochondrial Dysfunction in Neurodegeneration$0
P01 · FY2002 · AG
OXIDATIVE DAMAGE &MITOCHONDRIAL DYSFUNCTION IN ALS$0
P01 · FY2002 · AG
BIOENERGETICS IN ANIMAL MODELS OF HUNTINGTONS$383,508
R01 · FY2001 · NS
Mitochondrial Dysfunction in Alzheimer's Disease$325,440
R01 · FY2001 · AG
OXIDATIVE DAMAGE AND MITOCHONDRIAL DYSFUNCTION$231,922
P50 · FY2001 · NS
OXIDATIVE DAMAGE AND MITOCHONDRIAL DYSFUNCTION$73,467
P50 · FY2001 · NS
BIOENERGETICS IN ANIMAL MODELS OF HUNTINGTONS$50,000
R01 · FY2001 · NS
Mitochondrial Dysfunction in Neurodegeneration$0
P01 · FY2001 · AG
OXIDATIVE DAMAGE &MITOCHONDRIAL DYSFUNCTION IN ALS$0
P01 · FY2001 · AG
BIOENERGETICS IN ANIMAL MODELS OF HUNTINGTONS$373,612
R01 · FY2000 · NS
OXIDATIVE DAMAGE AND MITOCHONDRIAL DYSFUNCTION$231,922
P50 · FY2000 · NS
Mitochondrial Dysfunction in Neurodegeneration$181,206
P01 · FY2000 · AG
OXIDATIVE DAMAGE &MITOCHONDRIAL DYSFUNCTION IN ALS$0
P01 · FY2000 · AG